Medscape is available in 5 Language Editions – Choose your Edition here.


Arteriovenous Fistulas

  • Author: Sateesh C Babu, MD; Chief Editor: Vincent Lopez Rowe, MD  more...
Updated: Oct 16, 2015


Vascular birthmarks encompass a group of vascular disorders that for a long time included conditions of various presentation and etiology. In 1996, the Workshop of the International Society for the Study of Vascular Anomalies (ISSVA) presented a new classification of this vast group of conditions (subsequently modified in 1998), which divided them into vascular tumors and vascular malformations.[1, 2] This allowed more systematic classification and management with less confusion in diagnosis of these often complex lesions.

Arteriovenous fistula (AVF), by definition, describes an abnormal communication between an artery and a vein. These communications are congenital; can occur at any point in the vascular system; and vary in size, length, location, and number. AVF is a term reserved for a singular communication between an artery and a vein that usually has an acquired etiology.

The first recorded case of an arteriovenous malformation (AVM) was in the late 16th century. In 1757, Hunter described an AVF as an abnormal communication between an artery and a vein. Krause in 1862 used injection studies of an amputated specimen to characterize the abnormal vasculature. In 1875, Nicoladoni described the reflex slowing of the pulse following occlusion of an artery proximal to an AVM.

In 1920, Halsted contended that an AVM could produce cardiac enlargement and observed that a congenital AVF without a nevus is rare. In 1936, Holman described the pathophysiology and natural history of AVMs; this publication forms the basis for today's knowledge. In 1967, Fontaine observed that puberty or pregnancy can cause enlargement of AVMs.

Promising advances are being made in the diagnosis and treatment of AVMs. These advances provide hope to patients who are affected by this sometimes debilitating disease.



In the classification of vascular anomalies currently employed, a division is made between tumors and malformations. The first group is characterized by high turnover of endothelium, whereas the latter is characterized by the presence of dysmorphogenesis with no evidence of abnormal epithelial turnover.

Vascular tumors

The most common vascular tumor is infantile hemangioma. It is seen shortly after birth, is more common in girls and in whites, and is congenital. These tumors are usually solitary but not infrequently they may be multiple and involve the liver, gastrointestinal (GI) tract, and central nervous system (CNS). They are characterized by three phases of growth, as follows[3] :

  • Proliferation
  • Involution
  • Involuted phase

The first phase is characterized by rapid growth of the tumor, bright red or bluish in color, firm, and tense in appearance. They may develop surface ulcerations and episodes of bleeding. The involuting phase usually begins at the end of first year of life and is characterized by decreased tempo of the tumor growth, with the gradual color fading from the center of the mass and less tense consistency. Transition to the involuted phase occurs during the second half of the first decade of life. Normal skin is restored in half of patients, and persistent skin changes such as telangiectasias, skin thinning and scarring may occur.

Other congenital tumors include tufted angioma, infantile fibrosarcoma, infantile myofibromatosis and kaposiform hemangioepithelioma.

Vascular malformations

Generally, congenital vascular malformations are inborn errors in embryologic development. Woollard described the development of the vascular system in three stages, as follows:

  • The first step is the condensation of undifferentiated cells into capillary blood spaces
  • The next stage involves the formation of a retiform plexus in which blood flows from an arterial to a venous side; the channels in the retiform plexus combine and regress to form the vessels in the vascular system
  • The last stage involves the development of axial arteries in the limb buds

The final product is a complex interplay among genetic, hormonal, biochemical, and chemical factors. Developmental arrest can occur at any point during vessel formation, creating different types of vascular malformations. The exact cause for the arrest is not entirely known. All AVMs are present at birth, but they are not always clinically evident. Stimuli during puberty or pregnancy or following minor trauma can precipitate clinical features of the malformation.

Vascular malformations are characterized by normal epithelial turnover and are usually sporadic; however, some of them have been linked to genetic disorders. They can be subdivided according to the type and size of vascular bed involved, as well as the rate of flow through them.

Capillary malformations

Capillary malformations are usually sporadic; they can be divided into slow-flowing Klippel-Trenaunay, Maffucci, and Proteus syndromes and fast-flowing Parkes Weber and Bannayan-Riley-Ruvalcaba syndromes. These malformations are frequently associated with dilated capillary vessels in the dermis, asymmetric overgrowth of the involved limbs, and sometimes multiple soft tissue tumors, abnormal development of venous and arterial systems, and the presence of port-wine stains (see the image below).

Buttock port-wine stain. Buttock port-wine stain.

Lymphatic malformations

Lymphatic malformations are usually related to genomic mutations and include Milroy disease, Meige syndrome, yellow-nail syndrome, and Noonan syndrome. They are usually characterized by abnormal development of different portions of the lymphatic system.

Venous malformations

Venous malformations are the most common vascular malformations. They are usually sporadic and may be present at birth but are not always clinically obvious and predominantly occur in the skin and soft tissue (see Presentation). They include glomuvenous malformation and blue rubber bleb nevus syndrome.

Arteriovenous malformations

AVMs have the presence of arteriovenous shunts in multiple capillary beds both on the skin and involving internal organs. They are usually accompanied by a bruit and hyperemia with prominent venous outflow (see Presentation). They are represented by hereditary hemorrhagic telangiectasia syndrome, also known as Rendu-Osler-Weber disease.

Although the pathogenetic mechanisms of AVMs are not completely understood, the hemodynamic alterations that lead to the clinical manifestations of AVMs have been described well.

An abnormal communication causes shunting of blood from the high-pressure arterial side to the low-pressure venous side. This creates an abnormal low-resistance circuit that steals from the high-resistance normal capillary bed (see the image below).

Hypertrophied subclavian artery resulting from low Hypertrophied subclavian artery resulting from low-resistance high-volume flow through an upper extremity arteriovenous malformation (AVM).

Blood follows the path of least resistance. Flow in the afferent artery and efferent vein increases, causing dilatation, thickening, and tortuosity of the vessels. If the resistance in the fistula is low enough, the fistulous tract steals from the distal arterial supply, actually causing a reversal of arterial flow in the segment distal to the AVF. This is known as a parasitic circulation. The parasitic circulation causes decreased arterial pressures in the distal capillary beds and can cause tissue ischemia.

The increased flow into the venous circulation does not necessarily cause higher venous pressures. However, it can cause vessel wall abnormalities, such as thickening of the media and fibrosis of the wall. These changes are known as arterialization.

The blood flow into the venous circulation causes turbulence, which is responsible for the palpable thrill. The thrill is dependent on the geometry of the fistula and does not represent volume of flow accurately.

In addition to the decreased distal arterial pressures, which might cause distal ischemia, peripheral venous pressures are increased, leading to swelling, visible veins (varicosities), and even ulcers in the limb.

The heart responds to the decreased peripheral vascular resistance by increasing stroke volume and cardiac output. This leads to tachycardia, left ventricular dilatation, and, eventually, heart failure.

Mulliken has described a system of classifying AVMs on the basis of structural criteria, as follows:

  • Truncal AVMs - These are usually hemodynamically active and tend to present in the upper limb, head and neck, and pelvis; the lesions are localized and composed of a mass of enlarged vessels
  • Diffuse AVMs - These are usually found in the limbs, more frequently in the lower limbs than the upper limbs; in contrast to the truncal type, the connections are small and numerous; they are hemodynamically less active
  • Localized AVMs - These are usually inconsequential hemodynamically because of higher resistance in the connections; the lesions are composed mainly of abnormal intercalated tissues, not masses of enlarged vessels

Any structural type of AVM can be hemodynamically active or stable.



The majority of AVMs are developmental errors that occur between weeks 4 and 10 of embryogenesis. The factors that cause these errors are unknown. Potential exogenous causes, such as viral infections, toxins, and drugs, have been implicated but not yet proven. Almost all AVMs are sporadic and nonfamilial, though a few syndromes (eg, Sturge-Weber, Klippel-Trenaunay) include inherited vascular abnormalities.

The most common etiology for acquired AVFs is penetrating trauma. AVFs also can occur from nontraumatic causes, such as erosion of an aneurysm into a neighboring vein or following surgery for therapeutic purposes (eg, access for hemodialysis).[4]



All AVMs are present at birth, but they are not always clinically evident. Stimuli during puberty or pregnancy or following minor trauma can precipitate clinical features of the malformation.[5]  AVMs occur with equal frequency among males and females.



Many congenital AVMs/AVFs may regress spontaneously. The large ones, over the years, may lead to cardiac decompensation and death. In acquired AVFs, death can occur from cardiac failure, infection (bacterial endocarditis), or rupture if the AVF is between a large artery and vein (like iliac or renal AVFs or aortocaval fistulas); however, the prognosis is excellent once the AVF is corrected.

Yakes et al obtained follow-up studies in 19 of 20 patients with AVMs treated with ethanol embolization.[6] All patients showed persistent occlusion of the malformation radiographically after as long as 24 months of follow-up.

Widlus et al treated 11 patients with cyanoacrylate embolization. During a 40-month follow-up period, 82% reported complete resolution of their symptoms and the remaining patients showed improvement. No patients reported worsening of their symptoms with embolization in these 2 series.[7]

Do et al treated 12 patients for pelvic AVMs with combined endovascular and embolosclerotherapy. During the medial follow-up period of 33.2 months, 10 showed no residual lesion and complete symptomatic relief; 2 experienced partial remission.[8]

Pearce reported experience in 15 patients with vascular malformations treated surgically. Five patients were lost to follow-up. Assuming that those patients did well and did not seek further intervention, two thirds of those undergoing excision improved; 13% were unchanged after surgical excision, and 20% were worse.

Prompt recognition is important for outcome. Brinjikji et al reviewed spinal dural AVFs (lesions that are commonly missed on imaging or misdiagnosed) diagnosed at their institution between January 1, 2000, and November 1, 2014.[9] They found that delays in diagnosing these AVFs led to a high incidence of additional disability that frequently could not be reversed by surgical or endovascular treatment.


Patient Education

Physicians must be aware of the subtle signs of AVF in order to make the correct diagnosis. Prominent veins in the leg in a young individual following trauma, which may be mistakenly diagnosed as simple varicose veins, and rapid onset of heart failure in an otherwise healthy person, which may be diagnosed as cardiomyopathy, are examples for the need to look further for the presence of AVFs.

Contributor Information and Disclosures

Sateesh C Babu, MD Professor of Clinical Surgery, New York Medical College; Chief, Vascular and Endovascular Surgery, Westchester Medical Center

Sateesh C Babu, MD is a member of the following medical societies: American College of Surgeons, American Heart Association, American Institute of Ultrasound in Medicine, American Medical Association, New York Academy of Sciences, Royal Society of Medicine, Society for Vascular Surgery, Stroke Council of the American Heart Association, Eastern Vascular Society, International Society of Endovascular Specialists

Disclosure: Nothing to disclose.


Mark D Morasch, MD, RPVI Vascular Surgeon, Section Head of Vascular and Endovascular Services, Billings Clinic; John Marquardt Clinical Research Professor in Vascular Surgery, Division of Vascular Surgery, Northwestern University, The Feinberg School of Medicine

Mark D Morasch, MD, RPVI is a member of the following medical societies: Society for Vascular Surgery, Western Surgical Association, Southern Association for Vascular Surgery, American Venous Forum, Vascular and Endovascular Surgery Society, Society for Clinical Vascular Surgery, Western Vascular Society, Midwestern Vascular Surgical Society, American College of Surgeons, American Medical Association, American Heart Association, Central Surgical Association, Western Vascular Society, Southern Association for Vascular Surgery

Disclosure: Nothing to disclose.

Igor A Laskowski, MD Assistant Professor of Surgery, Section of Vascular Surgery, New York Medical College, Westchester Medical Center

Igor A Laskowski, MD is a member of the following medical societies: American College of Surgeons, Society for Vascular Surgery, Americas Hepato-Pancreato-Biliary Association, Vascular and Endovascular Surgery Society, Transplantation Society

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Vincent Lopez Rowe, MD Professor of Surgery, Program Director, Vascular Surgery Residency, Department of Surgery, Division of Vascular Surgery, Keck School of Medicine of the University of Southern California

Vincent Lopez Rowe, MD is a member of the following medical societies: American College of Surgeons, American Heart Association, Society for Vascular Surgery, Vascular and Endovascular Surgery Society, Society for Clinical Vascular Surgery, Pacific Coast Surgical Association, Western Vascular Society

Disclosure: Nothing to disclose.

Chief Editor

Vincent Lopez Rowe, MD Professor of Surgery, Program Director, Vascular Surgery Residency, Department of Surgery, Division of Vascular Surgery, Keck School of Medicine of the University of Southern California

Vincent Lopez Rowe, MD is a member of the following medical societies: American College of Surgeons, American Heart Association, Society for Vascular Surgery, Vascular and Endovascular Surgery Society, Society for Clinical Vascular Surgery, Pacific Coast Surgical Association, Western Vascular Society

Disclosure: Nothing to disclose.

Additional Contributors

William H Pearce, MD Chief, Division of Vascular Surgery, Violet and Charles Baldwin Professor of Vascular Surgery, Department of Surgery, Northwestern University, The Feinberg School of Medicine

William H Pearce, MD is a member of the following medical societies: American College of Surgeons, American Heart Association, American Surgical Association, Association for Academic Surgery, Association of VA Surgeons, Central Surgical Association, New York Academy of Sciences, Society for Vascular Surgery, Society of Critical Care Medicine, Society of University Surgeons, Western Surgical Association

Disclosure: Nothing to disclose.


Dipen Maun, MD Staff Physician, Department of Surgery, Mount Sinai School of Medicine

Dipen Maun, MD is a member of the following medical societies: Alpha Omega Alpha, American Medical Association, and American Medical Student Association/Foundation

Disclosure: Nothing to disclose.

  1. Enjolras O, Mulliken JB. Vascular tumors and vascular malformations (new issues). Adv Dermatol. 1997. 13:375-423. [Medline].

  2. Chaithirayanon S, Chunharas A. A survey of birthmarks and cutaneous skin lesions in newborns. J Med Assoc Thai. 2013 Jan. 96 Suppl 1:S49-53. [Medline].

  3. Richter GT, Friedman AB. Hemangiomas and vascular malformations: current theory and management. Int J Pediatr. 2012. 2012:645678. [Medline]. [Full Text].

  4. Smith GE, Gohil R, Chetter I. Factors affecting the patency of arteriovenous fistulas for dialysis access. J Vasc Surg. 2011 Nov 7. [Medline].

  5. Weibel L. Vascular anomalies in children. Vasa. 2011 Nov. 40(6):439-47. [Medline].

  6. Yakes WF, Krauth L, Ecklund J, et al. Ethanol endovascular management of brain arteriovenous malformations: initial results. Neurosurgery. 1997 Jun. 40(6):1145-52; discussion 1152-4. [Medline].

  7. Widlus DM, Murray RR, White RI Jr, et al. Congenital arteriovenous malformations: tailored embolotherapy. Radiology. 1988 Nov. 169(2):511-6. [Medline].

  8. Do YS, Kim YW, Park KB, Kim DI, Park HS, Cho SK, et al. Endovascular treatment combined with emboloscleorotherapy for pelvic arteriovenous malformations. J Vasc Surg. 2011 Nov 1. [Medline].

  9. Brinjikji W, Nasr DM, Morris JM, Rabinstein AA, Lanzino G. Clinical Outcomes of Patients with Delayed Diagnosis of Spinal Dural Arteriovenous Fistulas. AJNR Am J Neuroradiol. 2015 Sep 3. [Medline].

  10. Brouillard P, Boon LM, Mulliken JB, et al. Mutations in a novel factor, glomulin, are responsible for glomuvenous malformations ("glomangiomas"). Am J Hum Genet. 2002 Apr. 70(4):866-74. [Medline].

  11. Biswas S, Chandran A, Radon M, Puthuran M, Bhojak M, Nahser HC, et al. Accuracy of four-dimensional CT angiography in detection and characterisation of arteriovenous malformations and dural arteriovenous fistulas. Neuroradiol J. 2015 Oct 1. [Medline].

  12. Pearce WH, Rutherford RB, Whitehill TA, et al. Nuclear magnetic resonance imaging: its diagnostic value in patients with congenital vascular malformations of the limbs. J Vasc Surg. 1988 Jul. 8(1):64-70. [Medline].

  13. Dobson MJ, Hartley RW, Ashleigh R, et al. MR angiography and MR imaging of symptomatic vascular malformations. Clin Radiol. 1997 Aug. 52(8):595-602. [Medline].

  14. Sloan GM, Reinisch JF, Nichter LS, et al. Intralesional corticosteroid therapy for infantile hemangiomas. Plast Reconstr Surg. 1989 Mar. 83(3):459-67. [Medline].

  15. Ricketts RR, Hatley RM, Corden BJ, et al. Interferon-alpha-2a for the treatment of complex hemangiomas of infancy and childhood. Ann Surg. 1994 Jun. 219(6):605-12; discussion 612-4. [Medline].

  16. Patel AM, Chou EL, Findeiss L, Kelly KM. The horizon for treating cutaneous vascular lesions. Semin Cutan Med Surg. 2012 Jun. 31(2):98-104. [Medline]. [Full Text].

  17. Palmaz JC, Newton TH, Reuter SR, et al. Particulate intraarterial embolization in pelvic arteriovenous malformations. AJR Am J Roentgenol. 1981 Jul. 137(1):117-22. [Medline].

  18. White RI Jr, Pollak J, Persing J, et al. Long-term outcome of embolotherapy and surgery for high-flow extremity arteriovenous malformations. J Vasc Interv Radiol. 2000 Nov-Dec. 11(10):1285-95. [Medline].

  19. Lee BB, Kim DI, Huh S, et al. New experiences with absolute ethanol sclerotherapy in the management of a complex form of congenital venous malformation. J Vasc Surg. 2001 Apr. 33(4):764-72. [Medline].

  20. Ambekar S, Gaynor BG, Peterson EC, Elhammady MS. Long-term angiographic results of endovascularly "cured" intracranial dural arteriovenous fistulas. J Neurosurg. 2015 Sep 25. 1-5. [Medline].

  21. Gillebert C, Van Hoof R, Van de Werf F, et al. Coronary artery fistulas in an adult population. Eur Heart J. 1986 May. 7(5):437-43. [Medline].

  22. Phillips AW, Chaudhuri A, Meyer FJ. Bilateral long saphenous bruits: a marker of aortocaval fistula. Eur J Vasc Endovasc Surg. 2006 Nov. 32(5):529-31. [Medline].

  23. Reidy JF, Anjos RT, Qureshi SA, et al. Transcatheter embolization in the treatment of coronary artery fistulas. J Am Coll Cardiol. 1991 Jul. 18(1):187-92. [Medline].

  24. Said SA, el Gamal MI, van der Werf T. Coronary arteriovenous fistulas: collective review and management of six new cases--changing etiology, presentation, and treatment strategy. Clin Cardiol. 1997 Sep. 20(9):748-52. [Medline].

  25. Said SA, Landman GH. Coronary-pulmonary fistula: long-term follow-up in operated and non-operated patients. Int J Cardiol. 1990 May. 27(2):203-10. [Medline].

  26. Sherwood MC, Rockenmacher S, Colan SD, et al. Prognostic significance of clinically silent coronary artery fistulas. Am J Cardiol. 1999 Feb 1. 83(3):407-11. [Medline].

  27. Tkebuchava T, Von Segesser LK, Vogt PR, et al. Congenital coronary fistulas in children and adults: diagnosis, surgical technique and results. J Cardiovasc Surg (Torino). 1996 Feb. 37(1):29-34. [Medline].

  28. Yamanaka O, Hobbs RE. Coronary artery anomalies in 126,595 patients undergoing coronary arteriography. Cathet Cardiovasc Diagn. 1990 Sep. 21(1):28-40. [Medline].

Buttock port-wine stain.
Lower extremity venous malformation.
Upper extremity arteriovenous malformation (AVM).
Hypertrophied subclavian artery resulting from low-resistance high-volume flow through an upper extremity arteriovenous malformation (AVM).
Hand angiogram demonstrating arteriovenous connections. Note the steal of blood from the fingertips.
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.